Expertise in
1
conditions

Olaf Eickmeier

Frankfurt Am Main, HE, DE 
Expertise in
1
conditions
Frankfurt Am Main, HE, DE 

Overview

Olaf Eickmeier practices practicing medicine in Frankfurt Am Main, Germany.

Mr. Eickmeier is highly rated in 1 condition, according to our data. His clinical expertise encompasses Cystic Fibrosis, Aspergillosis, Exocrine Pancreatic Insufficiency, and Ataxia-Telangiectasia.

He is actively involved in clinical research, co-authoring 44 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Frankfurt Am Main, HE, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Corona-Virus-Disease 2019 (Covid-19) Antibody Responses in Cystic Fibrosis
Corona-Virus-Disease 2019 (Covid-19) Antibody Responses in Cystic Fibrosis
Enrollment Status: Unknown
Publish Date: February 26, 2024
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
Enrollment Status: Completed
Publish Date: January 18, 2023
Intervention Type: Drug, Other
Study Drug: Lenabasum
Study Phase: Phase 2
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
Enrollment Status: Completed
Publish Date: September 04, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

44 Total Publications

Relating Improvement in Gastrointestinal (CFAbd-Score©) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients.
Relating Improvement in Gastrointestinal (CFAbd-Score©) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients.
Journal: Pediatric pulmonology
Published: August 15, 2025

Frequently Asked Questions about Olaf Eickmeier

Is Olaf Eickmeier a top-rated expert for Cystic Fibrosis?

MediFind is an objective health platform that identifies experts based on real-world data. Olaf Eickmeier is classified as an Distinguished expert for Cystic Fibrosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Olaf Eickmeier participate in research or clinical trials?

Yes. Olaf Eickmeier has published 44 articles and abstracts on conditions like Cystic Fibrosis. You can view a list of Olaf Eickmeier's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Eickmeier's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile